Phase I clinical, pharmacokinetic and pharmacodynamic study of SB939, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumours (Q34621838)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Phase I clinical, pharmacokinetic and pharmacodynamic study of SB939, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumours |
scientific article |
Statements
1 reference
Phase I clinical, pharmacokinetic and pharmacodynamic study of SB939, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumours (English)
1 reference
A R A Razak
1 reference
S J Hotte
1 reference
L L Siu
1 reference
E X Chen
1 reference
H W Hirte
1 reference
J Powers
1 reference
W Walsh
1 reference
L-A Stayner
1 reference
A Laughlin
1 reference
V Novotny-Diermayr
1 reference
J Zhu
1 reference
E A Eisenhauer
1 reference
1 February 2011
1 reference
1 reference
104
1 reference
5
1 reference
756-762
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference
1 reference
1 reference